Skip to content

Westlake Village, CA, March 24, 2017 – FlemingMartin is pleased to announce that Sienna Biopharmaceuticals, a company committed to novel medical dermatology and aesthetic medicines and therapies for diseases of the skin, has hired Richard “Ric” Peterson to be their new Chief Financial Officer.

Mr. Peterson brings more than two decades of financial expertise to Sienna Bio, having served as Chief Financial Officer for both Novan, Inc. (NASDAQ: NOVN) and Medicis Pharmaceutical Corporation. Under Mr. Peterson’s leadership, Novan completed a successful Initial Public Offering in September 2016. Earlier in his career, at Medicis, Mr. Peterson played an integral role in guiding the company’s tremendous growth, resulting in its 2012 acquisition for $2.6 billion by Valeant Pharmaceuticals International. Prior to joining Medicis, Mr. Peterson served as a senior financial auditor for PricewaterhouseCoopers. Mr. Peterson currently serves as a Director at Universal Insurance Holdings and he holds a degree in accounting from Arizona State University.

Further information can be found at the following link:


Sienna Biopharmaceuticals

Sienna Biopharmaceuticals is a medical dermatology and aesthetics company. Sienna is focused on developing safe and effective targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients.


Fleming Martin Color Logo Medium 72 Ppi FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms and CEOs of companies to build successful execution-focused management teams. FlemingMartin focuses in the Technology, Manufacturing, and Consumer Products & Services industries. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.